Another somewhat scary binary biotech scenario however it looked to be a well planned trial and the interim numbers look compelling. At the AGM they made it clear that a comprehensive deal will be quickly concluded if the trial is successful and it's then an attractive licensing proposition with a speedy entry in the EU, FDA P3 trial then US sales Ultimately it's all down to the trial result.
Ann: Clinical Trial Update, page-4
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
